Atkinson Edward Morrow III 4

What Happened

• Edward M. Atkinson III, EVP & Chief Technical Operations Officer at Vertex Pharmaceuticals (VRTX), was awarded a total of 7,817 performance shares (3,934 and 3,883 shares) on 2026-01-22. Both awards are reported as acquisitions at $0.00 per share (awards, not purchases). The awards were certified by the company’s compensation committee and are scheduled to vest in February 2026.

Key Details

• Transaction date: 2026-01-22 (reported on Form 4 filed 2026-01-26).
• Transaction code: A (award/grant); price reported: $0.00 per share.
• Share breakdown: 3,934 shares (related to a PSU grant from 02/01/2023) and 3,883 shares (related to a PSU grant from 02/12/2025) — total 7,817 shares.
• Vesting: the 3,934-share award will vest on 02/13/2026; the 3,883-share award will vest in installments beginning 02/24/2026 (per footnotes).
• Shares owned after the transaction: Not specified in the filing.
• Filing timeliness: Form 4 was filed on 2026-01-26 for a 2026-01-22 transaction; this meets the typical two-business-day filing window.

Context

• These were earned performance shares (PSUs) tied to prior PSU grants; the management development and compensation committee certified achievement of performance goals, triggering conversion to shares at vesting. This is an award/compensation event, not a market purchase or sale—so it does not directly signal buying or selling intent. Such awards are common forms of executive compensation and typically vest subject to the stated schedule and any remaining conditions.